Is Pathos profitable?

No. Pathos is pre-revenue, with CB Insights recording $0 in revenue as of May 5, 2026. The clinical-stage oncology AI company relies on venture funding, having raised roughly $447M to $467M total, including a $365M Series D in May 2025 at a $1.6B valuation.

Pathos AI Inc. is privately held and venture-backed, not publicly traded. It was founded in 2022 by Eric Lefkofsky and Ryan Fukushima. Its Series D closed May 15, 2025 at $365M, led by undisclosed investors, following earlier rounds from NEA, Revolution Growth, Lightbank, and Builders VC.

Could AI replace Pathos?

Unlikely to be replaced outright since Pathos's product is itself an AI drug-development platform (Foundry, Scout, Sprint), but its core differentiator, a multimodal oncology foundation model with Tempus and AstraZeneca announced April 23, 2025, has published no benchmarks as of July 2026, over 15 months later.

Who is Pathos's biggest competitor?

Tempus AI (NASDAQ: TEM) is simultaneously Pathos's data partner in a $200M deal announced April 23, 2025 and a public competitor in AI-driven oncology, a co-opetition dynamic. Other rivals include Recursion Pharmaceuticals, Schrodinger, Insilico Medicine, and Alphabet's Isomorphic Labs.

What is Pathos's drug pipeline?

Pathos's pipeline includes P-500, a PRMT5 inhibitor acquired from Prelude Therapeutics in August 2024 and now in Phase 1/2, and DO-2, a third-generation MET kinase inhibitor gained through its May 6, 2026 majority-stake acquisition of Belgium-based DeuterOncology.

Has Pathos published its AI foundation model results?

No. The Tempus and AstraZeneca multimodal oncology foundation model collaboration, a $200M deal announced April 23, 2025, has produced no published performance benchmarks as of July 2026, more than 15 months after the announcement.

United States · United States

Pathos

AI-driven oncology drug developer building cancer drugs from owned clinical assets and licensed data.

Losing its protection

Assessed 29 July 2026 · Evidence as of 29 July 2026

The structural protection is eroding.

On the recordSince 29 July 2026 · Checkable from 2026-2027 · Every call on the record Checkpoint: P-500 Phase 1/2 trial readout

The call

Pathos holds real drugs and rare data access, but no revenue and no published model results leave its outcome tied to unproven trial readouts.

Pathos is an AI company trying to discover new cancer medicines by analyzing patient data and biology patterns. The company has some experimental drugs in testing and gets special data from a partnership with AstraZeneca, but it has never sold a drug and has not published clear proof that its AI method works better than what other companies like Tempus or Isomorphic are building. Big pharma companies like Eli Lilly and Novartis are also building their own AI drug discovery teams, so Pathos has no real protection. The key thing that could change everything is whether Pathos's cancer drug trials succeed in patients over the next year or so, or whether it publishes real proof that its AI is better than competitors.

Why

AI pressure: Isomorphic Labs, Recursion Pharmaceuticals, and Tempus AI's own drug ambitions. Rivals run similar AI-drug pipelines, and Tempus, a data partner, could pivot into a direct pipeline competitor. Could AI do the core job? Unlikely.

Bigger players: AstraZeneca, Eli Lilly, Novartis internal AI R&D programs. Big pharma is building in-house AI oncology programs that could route around Pathos once its AZ collaboration ends. Could a giant copy it? Yes, easily.

What protects it. Exclusive multimodal data access via the Tempus/AstraZeneca deal plus two owned clinical assets, P-500 and DO-2, not just a model.

What would change this call

Publication of Tempus/AstraZeneca multimodal foundation-model benchmarks. Shows whether Pathos's data moat produces validated results or stays unproven.
Phase 1/2 readout for P-500 (PRMT5 inhibitor) within 6-18 months. Tests whether Pathos's AI-derived pipeline can clear a real clinical hurdle.
Whether Tempus AI launches its own competing drug pipeline. Would show Pathos's key data partner turning into a direct rival.

Key numbers

$365M Series D at $1.6B valuation (2025-05-15)
$0 recorded revenue (2026-05-05)
$200M Tempus/AstraZeneca multimodal data deal (2025-04-23)

Named risks

Pre-revenue with binary outcome dependent on P-500 and DO-2 trial readouts. Severity: high
No published Tempus/AstraZeneca foundation-model benchmarks 15+ months after April 2025 announcement. Severity: medium
Tempus is both exclusive data partner and direct commercial competitor. Severity: high
Big pharma (Lilly's TuneLab, AstraZeneca internal AI) can replicate capability with no structural barrier. Severity: medium
Headcount growth flat at 0.0% YoY through June 2026 despite large 2025 capital raise. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Tempus AI	contesting	Data partner and public competitor since $200M deal signed April 23, 2025
Isomorphic Labs	gaining on	Alphabet-backed rival already has running deals with Lilly and Novartis since Jan 2024
Eli Lilly (TuneLab)	gaining on	Big pharma building internal AI drug-development platform, no structural barrier to copying Pathos
Recursion Pharmaceuticals	contesting	Publicly traded AI-oncology peer (NASDAQ: RXRX) named in 2026-06 competitive analysis
Schrodinger	contesting	Named peer in AI oncology drug discovery as of June 2026

Questions people ask

Is Pathos profitable?: No. Pathos is pre-revenue, with CB Insights recording $0 in revenue as of May 5, 2026. The clinical-stage oncology AI company relies on venture funding, having raised roughly $447M to $467M total, including a $365M Series D in May 2025 at a $1.6B valuation.
Who owns Pathos?: Pathos AI Inc. is privately held and venture-backed, not publicly traded. It was founded in 2022 by Eric Lefkofsky and Ryan Fukushima. Its Series D closed May 15, 2025 at $365M, led by undisclosed investors, following earlier rounds from NEA, Revolution Growth, Lightbank, and Builders VC.
Could AI replace Pathos?: Unlikely to be replaced outright since Pathos's product is itself an AI drug-development platform (Foundry, Scout, Sprint), but its core differentiator, a multimodal oncology foundation model with Tempus and AstraZeneca announced April 23, 2025, has published no benchmarks as of July 2026, over 15 months later.
Who is Pathos's biggest competitor?: Tempus AI (NASDAQ: TEM) is simultaneously Pathos's data partner in a $200M deal announced April 23, 2025 and a public competitor in AI-driven oncology, a co-opetition dynamic. Other rivals include Recursion Pharmaceuticals, Schrodinger, Insilico Medicine, and Alphabet's Isomorphic Labs.
What is Pathos's drug pipeline?: Pathos's pipeline includes P-500, a PRMT5 inhibitor acquired from Prelude Therapeutics in August 2024 and now in Phase 1/2, and DO-2, a third-generation MET kinase inhibitor gained through its May 6, 2026 majority-stake acquisition of Belgium-based DeuterOncology.
Has Pathos published its AI foundation model results?: No. The Tempus and AstraZeneca multimodal oncology foundation model collaboration, a $200M deal announced April 23, 2025, has produced no published performance benchmarks as of July 2026, more than 15 months after the announcement.

Timeline

2026-06Headcount reaches 96 employees, up from 76 in Sept 2024, per CrustData
2026-05-06Pathos acquires majority stake in Belgium's DeuterOncology for MET inhibitor DO-2
2025-05-15Pathos raises $365M Series D at ~$1.6B post-money valuation
2025-05Iker Huerga, ex-AstraZeneca and Tempus executive, named Pathos CEO
2025-04-23Pathos, Tempus AI, and AstraZeneca sign $200M multimodal oncology foundation-model deal
2024-10-29Pathos closes $62M Series C at $600M post-money valuation
2024-08Pathos acquires PRMT5 inhibitor P-500 from Prelude Therapeutics
2022Pathos founded by Eric Lefkofsky and Ryan Fukushima
2021-07Pathos closes $10M Series A

Revision history

29 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

American Airlines Group Wayfair Safe Superintelligence Inc.